Companies › Autolus
1 active drug program in 7 registered trials: 4 Phase 1, 3 Phase 2; Neurology, Immunology, Oncology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Obecabtagene Autoleucel B-lymphocyte antigen CD19 binding agent | CD19 | Phase 2 | Lupus Nephritis; Systemic Lupus Erythematosus; Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia; Progressive Multiple Sclerosis … | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06333483 | Obecabtagene Autoleucel | Phase 1 | Systemic Lupus Erythematosus | Immunology | Sep 2027 |
| NCT06173518 | Obecabtagene Autoleucel | Phase 1 | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Oncology | Nov 2027 |
| NCT07053059 | Obecabtagene Autoleucel | Phase 2 | Acute Lymphocytic Leukemia (ALL) | Oncology | May 2028 |
| NCT07053800 | Obecabtagene Autoleucel | Phase 2 | Lupus Nephritis | Immunology | Aug 2028 |
| NCT07400029 | Obecabtagene Autoleucel | Phase 2 | Acute Lymphoblastic Leukemia | Oncology | Feb 2029 |
| NCT04404660 | Obecabtagene Autoleucel | Phase 1 | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Oncology | Jun 2029 |
| NCT07139743 | Obecabtagene Autoleucel | Phase 1 | Progressive Multiple Sclerosis | Neurology | Aug 2029 |
Cash and short-term investments of $202m on 2026-06-30; operating cash outflow about $183m a year; runway about 13 months at that burn, to Aug 2027; 0 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Shanghai Ming Ju Biotechnology Kyverna Therapeutics Beijing Yongtai Ruike Biotechnology Company Juventas Cell Therapy Turn Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.